Pulmonary Cell News 6.22 June 8, 2017 | |
| |
TOP STORYmiR-146a-5p Plays an Essential Role in the Aberrant Epithelial–Fibroblast Cross-Talk in COPD Human bronchial epithelial cells were co-cultured with control and COPD-derived primary human lung fibroblasts, and miR-146a-5p expression was assessed with and without IL-1α neutralizing antibody. [Eur Respir J] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors investigated the mitochondrial uniporter (MCU) activity after heat treatment and assessed whether astragaloside-IV suppresses heat-induced apoptosis in bronchial epithelial cells by inhibiting the activation of the MCU, mitochondrial depolarization and reactive oxygen species production. [Cell Physiol Biochem] Full Article Role of Human Rhinovirus in Triggering Human Airway Epithelial-Mesenchymal Transition Investigators showed that two different strains of human rhinovirus (HRV), which use two different cellular receptors, are each capable of triggering phenotypic changes consistent with epithelial-mesenchymal transition (EMT). Moreover, both HRV serotypes synergistically induced changes consistent with EMT when used in the presence of transforming growth factor-β1. [Respir Res] Full Article Scientists investigated whether human rhinovirus (HRV) infection induces a specific gene expression pattern in airway epithelial cells. Alveolar epithelial cell monolayers were infected with HRV species B. [PLoS One] Full Article The exposure of human alveolar epithelial A549 cells to lipopolysaccharide resulted in cell apoptosis, inflammatory cytokine production, enhanced glycolytic flux and reactive oxygen species increased. [Biochem Biophys Res Commun] Abstract LUNG CANCEROverexpression of FBXW7α induced zinc-finger 322A (ZNF322A) protein degradation, thereby blocking ZNF322A transcription activity and suppressing ZNF322A-induced tumor growth and metastasis in vitro and in vivo. [Oncogene] Abstract Investigators report that type Iγ phosphatidylinositol phosphate kinase (PIPKIγ) was highly expressed in lung cancer tissues and its expression level is critical for lung cancer cell proliferation, which may serve as a prognostic marker for lung cancer patients. [Oncogene] Abstract Researchers investigated the efficacy of transferrin receptor-targeted liposomal nanoparticle-based human antigen R siRNA (HuR-TfNP) therapy and compared to control siRNA-TfNP therapy both in vitro and in vivo using lung cancer models. [Mol Cancer Ther] Abstract The authors clarified whether shikonin causes necroptosis in non-small cell lung cancer cells and investigated the mechanism of action. Multiplex and caspase 8 assays were used to analyze effect of shikonin on A549 cells. [J Transl Med] Full Article HGF Induces EMT in Non-Small-Cell Lung Cancer through the hBVR Pathway Researchers showed that compared to transforming growth factor beta, fibroblast growth factor, and epidermal growth factor, hepatocyte growth factor (HGF) is an important cell factor for epithelial-to-mesenchymal transition (EMT) in NSCLC cell lines A549 and H460. [Eur J Pharmacol] Abstract | |
| |
REVIEWSTreatment Advances in Small Cell Lung Cancer (SCLC) A new understanding of the biology of SCLC has led to the development of novel drugs, of which the most promising are the immune checkpoint inhibitors and the antibody drug conjugate rovalpituzumab tesirine. [Pharmacol Ther] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
SCIENCE NEWSMerck announced updated overall survival findings from KEYNOTE-024, the Phase III study evaluating KEYTRUDA®, the company’s anti-PD-1 therapy, as a monotherapy compared to platinum-containing chemotherapy in the first-line treatment of patients with advanced NSCLC whose tumors express high levels of PD-L1. [Press release from Merck & Co., Inc. discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Genentech announced that the Phase III ALEX study showed Alecensa® significantly reduced the risk of disease worsening or death by more than half compared to crizotinib when given as initial treatment for people with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. [Press release from Genentech discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Incyte Corporation and Merck announced updated data from the advanced non-small cell lung cancer patient cohort of the ongoing Phase I/II ECHO-202 trial, evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy. [Press release from Incyte Corporation discussing research presented at the 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago] Press Release Catabasis Pharmaceuticals, Inc. announced positive preclinical data on CAT-5571, supporting its potential as an oral treatment for cystic fibrosis. [Press release from Catabasis Pharmaceuticals, Inc. discussing research presented at the 40th Annual European Cystic Fibrosis Society (ECFS) Conference, Seville] Press Release | |
| |
INDUSTRY NEWSYale School of Medicine Expands Partnership to Promote Clinical Trials and Training in Puerto Rico An expanded partnership between the Yale School of Medicine and research institutions in Puerto Rico is set to foster collaborative clinical research and training opportunities in both countries. [Yale University] Press Release The Indo-American Cancer Association (IACA) honored City of Hope’s Ravi Salgia, M.D., Ph.D., with the IACA Award for Outstanding Contributions to Oncology during its annual meeting. [City of Hope (Business Wire Inc.)] Press Release | |
| |
POLICY NEWSNSF Offers Arm’s-Length Defense of Trump’s 2018 Request President Donald Trump’s proposal for an 11.3% cut in spending at the National Science Foundation (NSF) may be dead on arrival in Congress. But that doesn’t mean congressional appropriators will be able to avoid any squeeze on NSF’s budget. [ScienceInsider] Editorial Critics Challenge NIH Finding that Bigger Labs Aren’t Necessarily Better A strident debate has erupted among biomedical researchers over a proposed National Institutes of Health (NIH) policy that would shift money from richer to poorer labs. The policy—which would limit investigators to the equivalent of three NIH grants—is based largely on an agency-led analysis of lab productivity. It found that once an NIH-funded lab grows to a certain size, each additional grant produces a smaller productivity boost. But NIH’s study, and one graph in particular, has drawn widespread criticism. [ScienceInsider] Editorial Trump Retains Collins as NIH Director President Donald Trump announced that he is keeping Francis Collins as director of the National Institutes of Health (NIH). Collins, who was appointed by former President Barack Obama in 2009, was asked to stay on temporarily after the election. The decision comes despite a recent call from some conservative members of Congress to fire Collins because he supports embryonic stem cell research. Collins has said he would return to full-time research if Trump asked him to step down. [ScienceInsider] Editorial
| |
EVENTSNEW 18th World Conference on Lung Cancer (WCLC) Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Staff Research Scientist – Lung Injury (St. Michael’s Hospital) Postdoctoral Researcher – Lung Cancer Biology (Memorial Sloan Kettering Cancer Center) Clinical Research Fellow – Lung Fibrosis (University of Oxford) Research Assistant/Associate – Regulation of Human Lung Development (University of Cambridge) Postdoctoral Researcher – Inhalation & Developmental Toxicology (Louisiana State University) Postdoctoral Scientist – Macrophage and Lung Fibrosis (University of Oxford) Faculty – Immunology of Lung Diseases (National Jewish Health) Research Administrator IV – Early Detection of Lung Cancer (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|